Loading...
•
Sep 30, 2023
Edwards Lifesciences Q3 2023 Earnings Report
Edwards Lifesciences reported strong Q3 2023 results, driven by double-digit sales growth and multiple new therapy approvals.
Key Takeaways
Edwards Lifesciences reported a 12% increase in sales to $1.48 billion in Q3 2023. The company's TAVR sales grew by 11%, and it received several regulatory approvals for its innovative therapies. The company reiterated its full-year 2023 financial guidance of 10 to 13 percent constant currency sales growth.
Q3 sales grew 12 percent to $1.48 billion; constant currency sales grew 11 percent.
Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent.
Q3 EPS of $0.63; adjusted EPS of $0.59.
Reiterated full year 2023 financial guidance of 10 to 13 percent constant currency sales growth
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards' full-year sales guidance remains unchanged for both the total company and each product group. The company continues to expect full-year total company and TAVR sales growth to be in the 10 to 13 percent range on a constant currency basis. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.50 to $2.60. For the fourth quarter of 2023, the company projects total sales to be between $1.45 and $1.53 billion and diluted earnings per share of $0.60 and $0.66.
Positive Outlook
- Full-year total company sales growth to be in the 10 to 13 percent range on a constant currency basis.
- TAVR sales growth to be in the 10 to 13 percent range on a constant currency basis.
- Full year 2023 adjusted earnings per share of $2.50 to $2.60.
- Fourth quarter of 2023, the company projects total sales to be between $1.45 and $1.53 billion
- Fourth quarter of 2023, diluted earnings per share of $0.60 and $0.66.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...